Sunday, 14 Jun 2015 08:40pm EDT
Living Cell Technologies Ltd:Announces results
from Phase I/IIa clinical study of NTCELL, an experimental regenerative cell
therapy being studied as a disease-modifying agent in Parkinson's disease.
Says study, conducted in four patients in New Zealand, met its primary endpoint of safety, showing NTCELL implantation was well tolerated, with no adverse events considered to be related to NTCELL.
Says NTCELL implantation also improved clinical features of Parkinson's disease in the four patients studied, as measured by validated neurological rating scales
and questionnaires, with improvement sustained at 26 weeks post-implant.
Says study, conducted in four patients in New Zealand, met its primary endpoint of safety, showing NTCELL implantation was well tolerated, with no adverse events considered to be related to NTCELL.
Says NTCELL implantation also improved clinical features of Parkinson's disease in the four patients studied, as measured by validated neurological rating scales
and questionnaires, with improvement sustained at 26 weeks post-implant.
No comments:
Post a Comment